Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Version of Record online: 29 OCT 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 9, pages 1628–1633, September 2012
How to Cite
Kopylov, U., Mazor, Y., Yavzori, M., Fudim, E., Katz, L., Coscas, D., Picard, O., Chowers, Y., Eliakim, R. and Ben-Horin, S. (2012), Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis, 18: 1628–1633. doi: 10.1002/ibd.21919
- Issue online: 9 AUG 2012
- Version of Record online: 29 OCT 2011
- Manuscript Accepted: 15 SEP 2011
- Manuscript Received: 27 AUG 2011
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.